Featured Research

from universities, journals, and other organizations

Gender, Time Of Day Affect Response To Vaccination

Date:
July 11, 2008
Source:
Wiley-Blackwell
Summary:
A new study in the journal Psychophysiology reveals that men, but not women, vaccinated in the morning produced a better peak antibody response to both hepatitis A and the influenza strain.

A new study reveals that men, but not women, vaccinated in the morning produced a better peak antibody response to both hepatitis A and the influenza strain.

Led by Anna Catriona Phillips of the University of Birmingham, researchers assessed the response to a hepatitis A vaccine in young healthy adults and also examined responses to the annual influenza vaccination in older community-based adults.

In the first study, participants consisted of 75 University of Birmingham students who were vaccinated with the hepatitis A vaccine during a morning session (10 am to 12 pm) or early evening session (4 pm to 6 pm). In the second study, 90 older adults attended their medical practice for the annual influenza vaccination and received the vaccination in the morning between 8 am and 11 am or in the afternoon between 1 pm and 4 pm.

Men vaccinated in the morning showed the strongest immune response. Almost twice as many men showed a twofold increase in antibody response when vaccinated in the morning as opposed to the afternoon.

“If we can replicate these findings in a randomized controlled trial, there would be implications for the time of day for vaccinating those at risk,” the authors conclude. “Adults could be vaccinated at a specific time of day to increase their protection against the flu.”


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Phillips et al. Preliminary evidence that morning vaccination is associated with an enhanced antibody response in men. Psychophysiology, 2008; 45 (4): 663 DOI: 10.1111/j.1469-8986.2008.00662.x

Cite This Page:

Wiley-Blackwell. "Gender, Time Of Day Affect Response To Vaccination." ScienceDaily. ScienceDaily, 11 July 2008. <www.sciencedaily.com/releases/2008/07/080709153145.htm>.
Wiley-Blackwell. (2008, July 11). Gender, Time Of Day Affect Response To Vaccination. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/07/080709153145.htm
Wiley-Blackwell. "Gender, Time Of Day Affect Response To Vaccination." ScienceDaily. www.sciencedaily.com/releases/2008/07/080709153145.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins